Novavax Shifts Focus to Partnerships and R&D

Biotech company reduces operating expenses and stabilizes balance sheet as it advances early-stage pipeline and explores new Matrix-M adjuvant applications.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Novavax (NASDAQ:NVAX) executives told investors the company made 'significant progress' in 2025 executing a strategy centered on partnering its Matrix-M adjuvant technology and advancing a smaller, earlier-stage internal pipeline, while continuing to reduce operating expenses and stabilize the balance sheet.

Why it matters

Novavax's shift away from a 'vertically integrated global commercial organization' focused solely on COVID-19 vaccines towards a leaner model centered on partnerships and R&D reflects broader industry trends as the pandemic response evolves. The company's ability to leverage its Matrix-M adjuvant platform and generate non-dilutive funding will be key to its long-term success.

The details

President and CEO John Jacobs said Novavax has moved from a 'vertically integrated global commercial organization with a singular focus on COVID' to a company focused on 'partnering and R&D,' supported by a lean operating model. The company highlighted a January agreement with Pfizer to utilize the Matrix-M adjuvant in two disease areas, as well as new and expanded material transfer agreements (MTAs) with other pharmaceutical companies. Novavax also achieved all $225 million in eligible milestones under its collaboration with Sanofi in 2025 and expanded the agreement to include Matrix-M in Sanofi's pandemic flu candidate program.

  • In early 2025, Novavax announced resolutions of Nuvaxovid advance purchase agreements (APAs) with Canada and New Zealand.
  • In January 2026, Novavax signed an agreement with Pfizer to utilize the Matrix-M adjuvant in two disease areas.
  • In February 2026, Novavax expanded an existing material transfer agreement (MTA) with a major global pharmaceutical company to explore an additional field.
  • In 2026, Novavax expects to earn a $75 million Sanofi technology transfer milestone, though the timing may be impacted by the completion of some tech transfer activities at a new manufacturing site.

The players

Novavax, Inc.

A clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases.

John Jacobs

President and CEO of Novavax.

Elaine O'Hara

Chief Strategy Officer of Novavax.

Ruxandra Draghia

Head of R&D at Novavax.

Jim Kelly

CFO of Novavax.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.